Medtronic stock has delivered a 25.7% return over the past three years, and the current valuation picture is mixed, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to a price that is roughly in line with where the shares trade while earnings multiples suggest the stock may still be on the cheap side.

• Over the last three years, Medtronic has returned 25.7%, which makes the current price more about whether that performance already reflects the underlying fundamentals.
• Investor focus is likely to fall on how consistently Medtronic can convert its medical device portfolio into steady cash flows. At the same time, the recent US$88 million Covidien hernia mesh verdict may weigh on how the market prices legal and reputational risk.
• Medtronic screens as undervalued on some measures but only passes 3 of 6 valuation checks. This is a mixed picture rather than a clear bargain, as shown by the value score of 3/6.

The issue now is whether Medtronic's current share price already reflects these cross currents in the intrinsic value estimate, market multiples, and legal overhang, or if there is still a margin of safety for new capital.

Where Does Medtronic Sit on Cash Flow?

The Discounted Cash Flow (DCF) model looks at the cash Medtronic is expected to generate and discounts it back to today. On this basis, Medtronic is built on sizeable cash generation, with latest twelve month free cash flow of about US$5.4b and projections that assume broadly stable rather than aggressive growth. That cash flow profile leads to an estimated intrinsic value of about $84.83 per share.

This compares to a current share price that implies the stock trades about 8.8% above that estimate, so the DCF points to Medtronic being slightly overvalued on cash flows alone. The recent US$88 million Covidien hernia mesh verdict helps explain why investors may be demanding a bit of extra caution premium on top of the intrinsic value output.

On the DCF numbers, Medtronic stock currently screens as roughly fairly valued with a slight tilt to being overvalued.

Medtronic is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Does Medtronic Look Undervalued on Earnings?

The P/E multiple suits Medtronic because earnings remain a key anchor for a mature medical equipment company with an established product portfolio.

Medtronic trades on a P/E of about 24.6x, which is below the Medical Equipment industry average of 27.2x and also below the peer group average of 33.0x. A fair P/E ratio of 30.7x has been estimated for the stock based on its profile within the sector. That fair ratio is higher than where the shares trade today, which points to a discount on earnings compared with what similar companies command.

This gap suggests the current share price does not fully reflect the earnings multiple implied by those benchmarks, even after the recent Covidien hernia mesh verdict and related legal questions.

On the P/E yardstick, Medtronic stock appears undervalued relative to both its industry and the fair multiple estimate.

The Medtronic Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this Medtronic valuation puzzle leaves off by spelling out which future assumptions on growth, margins and earnings would need to hold for Medtronic's stock to be worth meaningfully more or less than today's price on the Community page. Rather than relying on a single multiple or model, each narrative lays out the key drivers behind its fair value view so you can compare those assumptions with Medtronic's actual results over time.

Community views on Medtronic are split between a rebound story built on product momentum and a more cautious take that focuses on current metrics and execution risks.

Bull case: 6% undervalued

"Medtronic's investments and breakthroughs in digital health technologies, robotics (Hugo), next-generation sensors, and AI-enabled ecosystems (e.g., spine AiBLE, advanced neuromodulation) align with industry-wide digital transformation and minimally invasive trends..."

Bear case: roughly fairly valued

"Although analysts are showing some caution and issuing various price targets, I found the timing of entry favorable..."

Do you think there's more to the story for Medtronic? Head over to our Community to see what others are saying!

The Bottom Line

For Medtronic, the Discounted Cash Flow (DCF) work points to a share price that is already slightly ahead of the intrinsic value estimate, while earnings multiples still hint at some undervaluation versus peers. That split largely comes down to how you weigh cash flow timing and capital needs against the market's expectations for growth and sentiment toward medical equipment stocks. With broader valuation checks landing in a mixed range, the real question is whether the current discount on earnings is a genuine opportunity or compensation for legal and execution risks that deserve a longer leash.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.